Nektar Therapeutics (NKTR) Earnings Call Transcript & Summary
May 9, 2024
Earnings Call Speaker Segments
Vivian Wu
executiveThanks, Crystal, and good afternoon to all of you. We appreciate you being with us today. Joining us on this call are our President and Chief Executive Officer, Howard Robin; our Chief Research and Development Officer, Dr. Jonathan Zalevsky; our Chief Medical Officer, Dr. Mary Tagliaferri; and our Chief Business Officer, Jennifer Ruddock. Sadly, our Acting Chief Financial Officer, Sandra Gardiner, couldn't be with us on today's call because of an unforeseen family emergency. During this call, we plan to make forward-looking statements about our business, including statements about the therapeutic potential of and future development plans for drug candidates and research programs, when clinical studies will begin, and when clinical data for drug candidates will become available; when future clinical data presentations will occur and what the plans for them are; whether our collaboration agreements will be formed, how they will develop in the future, or whether they will succeed; what we expect following our corporate restructuring and reorganization; financial guidance; and certain other statements about the future of our business. Since forward-looking statements concern the future, they carry uncertainties and risks that are hard to predict, and many of these lie beyond our control. Our actual results could differ materially from these statements. Key risks and uncertainties are described in our Form 10-K filed on March 5, 2024, which you can find at sec.gov. We assume no obligation to update any of these forward-looking statements, whether because of information, future developments, or otherwise. A webcast of this call will be accessible on the IR page of Nektar's website at nektar.com. Before I turn the call over to Howard, I want to mention that our team is dialing in from various locations, and Howard will moderate the Q&A session for our team so that we can steer clear of technical issues during the session; we thank you for your patience; and with that, I'd like to hand the call to our President and CEO, Howard Robin. Howard?
Howard W. Robin
executiveThanks, Vivian, and I appreciate everyone being here with us today. We've kicked off 2024 carrying good momentum forward as we keep working to build a pipeline that ranks among the best in its class, centered on immunology and inflammation. A central objective for us is tackling the fundamental shortage of regulatory T cells, which sit beneath a variety of severe immune conditions. Within our pipeline we hold a number of important immunology targets and first-in-class mechanisms, among them our lead program REZPEG and the newly added TNFR2 agonist NKTR-0165 — both aimed at immune-resolving pathways; during Q1, we kept achieving meaningful progress on the REZPEG program. As everyone is aware, REZPEG is being assessed in a phase 2b trial for moderate to severe atopic dermatitis, a study that got underway last year, and at present it is enrolling patients across the globe. I'm happy to share today that enrollment remains on schedule, positioning us to report top-line data from the trial's 16-week induction period during the first half of 2025. Roughly 30 million individuals in the U.S. by itself are living with atopic dermatitis, and among those patients, half receive a diagnosis of moderate to severe disease. Biologic therapies for atopic dermatitis make up a multibillion-dollar market that keeps expanding, and we're thrilled that REZPEG might turn into a highly differentiated option for atopic dermatitis, an illness where substantial unmet need persists for safe and durable treatments. Our view is that REZPEG could represent a major step forward in treating atopic dermatitis. The updated, corrected phase 1b data we presented at last year's EADV conference demonstrated a striking 83% reduction in EASI scores across 12 weeks of treatment. Importantly, that study further revealed REZPEG produced durable responses 36 weeks after treatment concluded, which raises the possibility that REZPEG may deliver an immunomodulatory effect. During the most recent quarter, we launched our second phase 2B trial of REZPEG, this one in patients suffering from severe to very severe alopecia areata. We see a substantial opportunity for REZPEG to assist people living with this devastating condition. Almost seven million individuals in the U.S. by itself have or will contract alopecia areata. This condition heavily impacts patients' quality of life, and the therapies available right now lack durability, come with high relapse rates, and pose considerable safety risks. As a result, a pressing unmet medical need exists for new treatment options. Enrollment began in March for the phase 2B alopecia areata trial, which will assess REZPEG across a 36-week induction period. Jonathan Zalevsky will discuss this program in greater detail later during the call. Enrollment for this trial is proceeding as planned, and we anticipate reporting top-line results in the first half of 2025. Beyond that, we're moving NKTR-0165 forward — our novel TNFR2 agonist antibody. TNFR2 has been demonstrated to strengthen the suppressive effects along with the overall functional characteristics of Tregs. This program rests on what we've gained through our extensive experience with REZPEG and within the Tregs field, and it offers a promising first-in-class, differentiated mechanism for multiple sclerosis, ulcerative colitis, and a variety of other autoimmune diseases. Right now, we're running IND-enabling studies, aiming to file an IND around the middle of 2025. I'm happy to share that our preclinical findings have been chosen for a presentation at EULAR, and we can't wait to show the first data from this program. Turning to NKTR-255, our IL-15 oncology program, we're carrying on our clinical efforts alongside our partners, and we anticipate results from a number of them during this year. In line with our strategic emphasis going forward on immunology and inflammation, we keep assessing opportunities for strategic partnership around this program. Last, Nektar holds a solid financial position, with a cash runway stretching well into 2026's third quarter. I feel immense pride in our Nektar team, and we remain sharply focused on carrying out the REZPEG development plans so we can hit value-enhancing data milestones next year; with that, I'll pass the call to J.Z. for an R&D discussion. J.Z.?
Jonathan Zalevsky
executiveThanks, Howard. Let me start with REZPEG. Among IL-2 Treg mechanisms being developed, this one is the furthest along. When it comes to atopic dermatitis, people living with this condition still contend with three key challenges. The first is that they need greater efficacy — a bigger response and faster relief. To illustrate, roughly 50% of those given biologics targeting IL-13 see a meaningful clinical improvement. The second challenge is that durable responses and therapy-free remission remain out of reach. When today's treatments stop, symptoms come back quickly. The third is that we don't have options with safety profiles that hold up over the long term. Given how chronic this disease is and how dosing must continue indefinitely, that matters a great deal. We see significant opportunities in this disease state that REZPEG may be able to tackle. In our phase 1b atopic dermatitis data, REZPEG showed efficacy that depended on dose, plus durability that was encouraging, observed well after patients finished the 12-week induction period. In fact, the same pattern emerged for patient-reported outcomes and physician-assessed endpoints alike: quick onset of effect, dose dependence, and control that lasted a long time. On top of that, REZPEG had a well-tolerated profile, and antidrug antibodies were not induced in patients receiving it — something that has been reported in certain examples within the IL-2 mutein class. Later this year, we look forward to publishing in a peer-reviewed journal new translational biomarker data from the study, together with the clinical and safety data from atopic dermatitis and psoriasis. The speed at which it acts and the extended disease control that follows the end of dosing matches or beats what dupilumab or JAK inhibitors deliver. Because of these promising data, KOLs are very enthusiastic about the potential for long-lasting responses and infrequent maintenance dosing with REZPEG in atopic dermatitis. In our phase 2b study of REZPEG in biologic-naïve atopic dermatitis patients, enrollment is progressing on track. We aim to enroll approximately 400 patients, with three different REZPEG regimens versus placebo, assessed across a 16-week induction period. Following induction, patients who meet a threshold to move from induction into maintenance will be re-randomized to one of two maintenance regimens at different dosages, on either a once-a-month or once-every-three-months dosing schedule. We expect initial data in the first half of 2025. Now turning to alopecia areata — we believe REZPEG has a strong scientific rationale in this indication. Alopecia areata is likewise a skin disease in which the immune system begins attacking the hair follicles, undermining the ability of stem cells to grow hair. When the immune attack persists, it causes the hair follicle to release the hair entirely, which results in baldness. From a biological standpoint, REZPEG, via its central pathway of Treg rescue, is uniquely positioned to address the diversity of immunopathology, offering broad potential for targeting multiple dermal diseases, alopecia areata included. Specifically, alopecia areata represents a breakdown of immune privilege in the hair follicle; so what does this mean, exactly? Okay, so hair follicles under normal conditions sit in what's called a state of immune privilege. Put another way, you won't find immune cells there, there's no MHC expression, and essentially none of the components of the immune system are present within the follicle. It's understood that keeping the immune system out is necessary so that healthy stem cells — long-lived and continuously working — can keep producing hair over the course of our lives. When someone has alopecia areata, that immune privilege inside the hair follicle collapses: the immune system moves in, inflammation follows, and all of this results in hair loss and ultimately complete baldness. Preclinical work, both in vitro and in mice engrafted with human alopecia skin samples, has demonstrated that Tregs play an essential role in bringing back and sustaining immune privilege, which makes them a novel therapeutic approach for treating this disease. So as a result, we think the Tregs mechanism behind REZPEG is capable of restoring immune privilege and might deliver durable disease control, and that would be game-changing for this indication. In alopecia areata, JAK inhibitors are the sole approved agents, and treatment is lifelong; on JAK inhibitors, a patient may need anywhere from 6 to 12 months before hair regrows. When a patient discontinues a JAK inhibitor — which can occur for many reasons, toxicity among them — their hair rapidly falls out once more. There's a substantial unmet need among this patient population for tolerable options that give durable responses, and for those reasons we see an opportunity for REZPEG to emerge as a novel biologic therapy in alopecia areata. Enrollment is well underway in the phase 2b trial of REZPEG in alopecia areata. About 80 patients are planned for this study, all with severe to very severe disease, randomized between REZPEG and placebo. The treatment period runs 36 weeks, with observation extending to 60 weeks overall. Mean % improvement in SALT — the Severity of Alopecia Tool — at week 36 serves as our primary endpoint. A range of secondary endpoints will also be assessed, among them the proportion of patients seen to have differing degrees of improvement in SALT score; top-line data are expected in the first half of 2025. Now let me move to NKTR-0165, our TNFR2 agonist antibody. TNFR2 shows high expression on Tregs, myeloid suppressor cells, regulatory B cells, neuronal cells, and others, and agonism at TNFR2 has been demonstrated to potentiate effector functions, suppressive functions, and maintenance of lineage stability in Tregs, particularly within non-lymphoid tissue compartments. Without TNFR2, the phenotypic outcome is autoimmunity along with other genetic conditions resembling FOXP3 loss of function. Conversely, when it's present and its signaling is activated, that's been linked to immunoregulatory function and protective effects across multiple cell populations and tissues in the body. The TNFR2 agonist program rests on many years of Tregs experience that we've accumulated through studying REZPEG. TNFR2 stands out as the TNF superfamily member found in greatest abundance on Tregs, and it serves as the primary force behind NF-κB signaling within those cells — that's the reason this program and target generate so much enthusiasm from us. For this program, we partnered with a company specializing in AI-driven antibody engineering, screening a broad range of TNFR2 selective binding antibodies to find novel ways of agonizing TNFR2. The distinctive and differentiated profile of the antibodies we discovered has us quite enthusiastic, and we're pushing these toward the clinic at a rapid pace; we expect to submit our IND for this program midway through next year. Among the indications that TNFR2 agonism might target are multiple sclerosis, mucosal immunology conditions including ulcerative colitis of the GI tract or other oral mucosal diseases, and even dermal autoimmune conditions such as vitiligo. As Howard noted, data from our preclinical work on this program has been chosen for a poster presentation at EULAR. This marks the first look at this novel, therapeutically active anti-TNFR2 agonist antibody, and we look forward to sharing these findings. Interest keeps building for a novel, selective TNFR2 agonist such as NKTR-0165, and as we proceed with our IND-enabling studies, we'll remain open to the possibility of collaborating with companies that have interest in these areas to strategize on the optimal path forward. And lastly, shifting to our IL-15-based oncology program, NKTR-255. We think the IL-15-based mechanism of action holds promising potential as a combination agent alongside cell therapies and other mechanisms like checkpoint inhibitors; we're investigating the best partnering routes for continued development of this drug candidate. We are wrapping up our Nektar-sponsored trial combining NKTR-255 with the approved CD19 CAR-Ts, BREYANZI and YESCARTA, for treating patients with large B-cell lymphoma. A separate investigator-sponsored trial from Fred Hutch is likewise assessing the combination of NKTR-255 and BREYANZI, and we intend to present data from this ongoing study at a medical meeting later this year. We remain in collaboration with Abel Zeta, a leading cell therapy company, to assess NKTR-255 alongside their tumor-infiltrating lymphocytes, or TILs, TIL therapy in an ongoing phase 1 clinical trial involving patients with advanced non-small cell lung cancer who don't respond to anti-PD-1 therapy. Finally, we're continuing our work with our partner, Merck KGaA, in the phase 2 JAVELIN Bladder Medley study, assessing NKTR-255 combined with BAVENCIO, and we expect to report interim data, including PFS, later this year; with that, I'll hand the call over to Jennifer for a review of our financial guidance. Jennifer?
Jennifer Ruddock
executiveThanks, Jay Olson, and good afternoon to all of you. We closed out the quarter holding $326 million in cash and investments, and our balance sheet carries no debt at all. Our financial standing is still solid, and we continue to expect to finish 2024 with somewhere between $200 million and $225 million in cash and investments. That cash guidance factors in a $30 million private placement of pre-funded warrants that closed in Q1, along with a $15 million cash payment stemming from an amendment to the 2020 agreement with HealthCare Royalty, which also closed in Q1. Our cash runway now reaches well into the third quarter of 2026, carrying us past a number of important data milestones, among them, naturally, the top-line data from the Phase 2 REZPEG studies. Let me now quickly walk through our quarterly financials and restate our financial guidance for 2024. Revenue came in at $21.6 million for the first quarter of 2024. We continue to anticipate full-year revenue of $75 million-$85 million, comprising $55 million-$65 million in non-cash royalties and $20 million-$25 million in product sales. R&D expense for the first quarter of 2024 totaled $27.4 million, and we still expect full-year R&D expense to fall in the $120 million-$130 million range. G&A expense in Q1 came to $20.1 million. We continue to expect full-year G&A expense of $70 million-$75 million. Our 2024 non-cash interest expense guidance is likewise unchanged and is projected at $20 million-$25 million. Net loss for the first quarter of 2024 was $36.8 million, or $0.19 per share. I should point out that the per-share loss reflects a rise in weighted average shares outstanding during the first quarter relative to a year ago. That increase is mainly tied to the impact of the PIPE financing in March and is partly offset by the impact of the shares we bought back from Bristol-Myers in February. Both of these items will be fully captured in the weighted outstanding share calculation at the close of the second quarter. As I said before, we still expect to finish 2024 with $200 million-$225 million in cash and a runway reaching well into the third quarter of 2026. With that, let's open the call for questions. Crystal?
Jay Olson
analystHey there, congratulations on everything you've accomplished, and I appreciate you fielding the questions. Could you discuss how enrollment is going for REZPEG in both AD and AAA, and is that enrollment matching up with what you projected internally?
Howard W. Robin
executiveSure, I'll have Mary give you the full picture on that. Enrollment is going exactly as we intended, but I'll let Mary walk through it in a bit more depth. Mary, please go ahead.
Mary Tagliaferri
executiveAppreciate that, Howard, and thanks for raising it, Jay. Let me take you back: our phase 2B trial kicked off in October of last year, and the goal is to randomize 400 patients who have moderate to severe atopic dermatitis, all of whom have never received a biologic. Like Howard and Zalevsky both said during this call, we remain fully on schedule to report top-line results from the 16-week induction period during the first half of 2025. Enrollment is going according to plan, and at this moment the trial is accepting patients across the United States, Canada, Australia, and Europe. What our investigators keep telling us is how eager they are to study REZPEG, because its mechanism of action for boosting Tregs is novel. Another thing they responded to was the strong atopic dermatitis data Dr. Jonathan Zalevsky presented at EADV a year ago. Howard and Jay already noted that the phase 1b demonstrated an 83% reduction in mean percent change in EASI, and despite a small sample size, we achieved statistical significance versus placebo, so physicians are equally enthusiastic about how potent the efficacy is. As clinicians, they know the real-world evidence well, which shows durability falls short when patients are treated with Dupixent. Literature tells us that 79% of patients who stop Dupi lose control of their disease after roughly four months without treatment. That's why practicing dermatologists really value the remittive effect Jay described, along with the durable responses observed off treatment for nine months among those dosed in the phase 1b. One last point: site staff and investigators alike genuinely value REZPEG's very well-tolerated safety profile. Turning now to alopecia, we launched that phase 2b trial in March. Per Jay Olson, we'll assess two doses against placebo, using SALT scores as the primary efficacy endpoint. About 28 sites across the U.S., Canada, and Poland will take part. Once again, enrollment is completely on track, which sets us up to have data in the first half of 2025.
Jay Olson
analystThanks a lot; that's really useful. I truly value the extra detail regarding REZPEG's encouraging efficacy, particularly for atopic dermatitis. Perhaps, if I may build on what you said regarding safety, given that a competitor's phase 2 atopic derm trial was shut down recently after a clinical hold, could you share whatever feedback the DSM-B is providing about REZPEG's safety and atopic derm?
Mary Tagliaferri
executiveCertainly. At this point, 9 clinical trials have been run within the REZPEG program, and 592 patients have received REZPEG as of now. Roughly 150 patients across the program had been assigned to placebo in our studies. Once all the data came back to us from Lilly for those finished trials, our Stuart biostatisticians along with the drug safety team put together pooled safety tables, letting us examine REZPEG's safety profile more closely; we intend to publish this information, though at a very high level, several truly important key conclusions emerge from the integrated safety data. Number one, the side effect occurring most often is injection site reactions. Usually these are mild to moderate, appearing mainly during the first or second cycles, and as time passes their frequency and duration diminish. Yet most significantly, REZPEG isn't a classic immunosuppressant, and it was very encouraging to find no elevated infection risks. Therefore, no rise in COVID cases appeared on REZPEG arms compared with placebo. No heightened risk is observed for herpes reactivation, whether herpes simplex or herpes zoster. Conjunctivitis doesn't appear as a greater risk on REZPEG, and facial erythema, red face, or arthralgia also don't appear. Now, turning to that other hepatotoxicity matter you mentioned concerning the other agent, which matters greatly, no elevated risk is seen for hepatotoxicity or for AST or ALT increases. We do observe that certain patients show rises in eosinophilia, yet there are no instances of symptomatic eosinophilia of any type, tissue damage, or organ involvement. Finally, we observed a greater incidence of severe treatment emergent AEs and serious AEs solely within the placebo group when compared against REZPEG; the safety profile pleases us greatly, and once more, our investigators are delighted to advance this compound in clinical testing, given the well-tolerated safety profile for a biologic and, once more, no sign of heightened hepatotoxicity risk. Thanks for bringing that up, Jay.
Jay Olson
analystThanks a lot for that thorough rundown on REZPEG's safety profile. Could I possibly slip in a further question regarding the TNFR2 program — would you mind discussing the preclinical results you expect later in the year, plus the thinking behind clinical development and how you're ranking the various indications under consideration?
Jonathan Zalevsky
executiveYes, of course. Hi, Jay — J.Z. here. So EULAR takes place in June, correct? That means we'll be presenting in about a month, and Vienna is the host city this year. As for what we'll share: we'll be presenting our work on how the antibody was discovered. We adopted what you could call a novel strategy for identifying agonists — one portion of that clearly stemmed from AI-based computational engineering, while another portion involved the way we screened for agonism. That will be one component of the presentation. It characterizes how antibody specificities and epitopes were discovered. After that, we've naturally advanced those into preclinical development candidates; so that type of data gets presented as well. So there will be binding data, specificity data, cell signaling data, shifts in the sort of cellular architecture you'd anticipate seeing upon agonizing TNFR2, and additionally some animal data demonstrating biological activity and clinical efficacy across certain animal models; so for us this represents an important milestone — the inaugural preclinical presentation of our efforts in this program within a public forum, under the auspices of a highly significant and pivotal medical meeting, since EULAR is an extremely large conference; when it comes to indications, something quite distinctive about TNF2 is that as regulatory T cells travel progressively farther from either the thymus, the blood, or secondary lymphoid organs such as the lymph nodes, the spleen, and so forth, once they enter non-lymphoid tissue, their dependence grows much greater on an NF-κB signal and on the actions of ligands for TNF2 as a crucial transducer of NF-κB. We're examining additional indications, which explains why, for instance, conditions involving mucosal immunology rank very highly for us. We understand that within the mucosa, Tregs face a wholly distinct cytokine environment. IL-2 is present at very low levels in those sorts of settings, correct? Consequently they require a different type of signal; so ulcerative colitis along with indications affecting either the lower or the upper mucosa are ones we're putting at the top of our priorities. And we also understand that within the CNS context, especially concerning the role of myelin and demyelination and the part TNFR2 plays in regulating some of that biology — which has been demonstrated quite elegantly in animal preclinical models and mice — that provides another rationale for why multiple sclerosis likewise stands as a high-priority indication for us. So that's merely a taste of how we're approaching the program; though without question, those two things go hand in hand, and they complement each other strongly. So essentially, when you look at REZPEG alongside NKTR-0165, those two together sort of cover the two primary biological pathways involved in Treg biology.
Jay Olson
analystThat's excellent. I'm eager for it. Thanks once more for fielding every question, and congratulations on how much has moved forward.
Jonathan Zalevsky
executiveThank you, Jay.
Roger Song
analystThanks a lot. Appreciate the update and for fielding every question. Perhaps one brief item about REZPEG — what comes next once we have the phase 2b data? I realize a longer follow-up period is needed, yet on the top line, what's the plan going forward for those 2 indications? Thank you.
Howard W. Robin
executiveAll right, I'm going to let Mary handle that one. Still, it's clear we've stated that results from the first 16-week induction period would arrive in the first half of next year, and after that, naturally, we'll be examining how durable the response is. Mary, though, can give you more detail on that.
Mary Tagliaferri
executiveRight, thanks Howard, and thanks Roger. Fortunately for us, getting an agent approved when you're creating it for both atopic dermatitis and alopecia follows a really straightforward route. When it comes to atopic dermatitis, if our phase 2B trial turns out positive and we demonstrate a statistically significant benefit on the EASI score, we'd begin preparing for the phase 3 program. Within that phase 3 program, you usually test either one or two doses of your drug against placebo. On top of that, the primary efficacy endpoint across these two monotherapy trials against placebo sits at the 16-week mark. Certain other agents examine a 24-week induction period. As far as the FDA is concerned, the primary efficacy endpoint is the VIGA, while in Europe it's a co-primary endpoint consisting of VIGA plus the EASI 75; beyond those two phase 3 monotherapy trials, you'd normally run a combination trial using topical corticosteroids against topical corticosteroids by themselves, and that makes up the phase 3 program for atopic dermatitis. Enrolling in these trials is fairly simple; it usually takes roughly a year to fill those studies; alongside efficacy, you need approximately 600 patients who've been exposed to REZPEG at your highest dose across 12 months. Then when it comes to alopecia areata, you'd have two phase 3 trials, and they'd pit REZPEG against placebo. Once again, the induction period runs somewhat longer than what you'd see with atopic dermatitis, since hair takes more time to grow, so the induction period typically comes to about 36 weeks. Clearly there's no combination trial that would get run. By contrast with atopic dermatitis, which calls for two phase 3 trials, in alopecia areata there would be two.
Roger Song
analystGreat. Thanks for the detail. Then maybe if you can comment on your ongoing litigation with Eli Lilly for your REZPEG and any kind of updates from that end? Thank you.
Howard W. Robin
executiveSure. Look, as you know, the court ordered us to go to mediation with Lilly, and that's actually scheduled for next week. We're not going to comment on the results of this. We'll comment when we reach a solution with Lilly, but we will be mediating with them. They were clearly responsible for an egregious error that changed the dynamics of REZPEG. And clearly, if you look at the original data and then you look at the corrected data, REZPEG seems to function very, very well in atopic dermatitis, and it appears to be highly competitive, very different from their initial calculations. And they filed a counterclaim, which, of course, has very little merits behind it. And certainly, we don't expect that to be valued by the court, nor do we expect that we will owe Lilly any money. Not at all. I think this will sort itself out over the coming year. I can only tell you that the judge did not dismiss our case against Lilly and ordered us into mediation. We'll see how that goes.
Roger Song
analystGreat. Yeah, I'm excited for it. Thanks.
Nick Alford
analystHi, Jess — it's Nick Alford here. I appreciate you taking our questions. Perhaps just one brief item as we go back to how REZPEG was designed. From what I gather, attaching PEG creates a sort of uneven preference toward IL-2 or alpha instead of beta, but could you tell me again precisely at what location on the IL-2 molecule the PEG sits in order to produce that biased binding?
Howard W. Robin
executiveJay, do you want to answer that?
Jonathan Zalevsky
executiveRight, hi Nick. So that granularity hasn't been disclosed by us; a great deal of information regarding how REZPEG is designed was put out in our initial manuscript in the Journal of Translational Autoimmunity, but which amino acids, say, get pegylated — that hasn't been disclosed. What I'm able to say is that our experience designing molecules of this sort is extensive, and within REZPEG this molecule closely resembles certain of the original foundational molecules — PEGASYS or Neulasta, for instance — that we created alongside a great many partners across many decades; and then as for the mechanism, those biological consequences of pegylation confer the proper receptor occupancy; they confer the proper signaling duration. And that is what provides REZPEG with this ongoing capacity to renew regulatory T cells when dosing continues. We hold data from dosing individuals across 3 months, across 6 months, where that pharmacodynamic effect is maintained; that's the aim of the treatment, after all.
Nick Alford
analystThat’s clear. And perhaps just a quick.
Jonathan Zalevsky
executiveThat’s clear.
Nick Alford
analystYeah, that tracks. And maybe one fast additional question while we're on this topic. Obviously, clinical data exists, plus data from humans. But to grasp things a little better — I recall there being certain observations where NK cell activation showed up at higher doses in different, earlier models. Have any such cases turned up in the clinic, at the doses you're currently testing, and if that happened, what would it look like — in either the AD or the alopecia areata trial?
Jonathan Zalevsky
executiveYes. That's something we've put out there too. In our second publication, covering findings from our phase 1A and phase 1B trials, we showed that type of result. So it does appear in certain individuals, though not everyone. It builds over time. REZPEG, to give an example, brings about TREGs that rise right away, starting with the initial dose. NK cells show up inconsistently. Not everyone has them; and when they do appear, they tend to take a while longer before becoming evident. Then there's something quite intriguing: we altered how the NK profile skews, correct? As you're aware, CD56 bright and CD56 dim NK cells exist, and the two vary when it comes to FcγR3a (CD16) expression. Under typical circumstances, or rather, I suppose in a particular immunological state, you generally find mostly CD56 dim, CD16 high. REZPEG doesn't bring those cells on; what it brings on is the CD56 bright, CD16 negative NK cells, which a lot of people have suggested actually carry out regulatory roles. So yes, it brings NK cells on inconsistently, and whenever that happens, it pushes them toward that different, potentially more regulatory phenotype. Those findings have been published by us.
Nick Alford
analystGood. I appreciate you coming back to that.
Andy Hsieh
analystExcellent, and thanks for fielding our questions. We’re grateful for the update. I’ll keep it to two brief items. First, regarding the TNF-R2 validation you brought up, Zalevsky — to make sure I understand, do you mean validation from human genetics across a population, in order to reduce risk around the mechanism? Then, second, on 255, meaning the phase 2 JAVELIN Bladder Medley trial, I believe the most recent time you spoke about it, you said a second-half update might come. So I’m wondering first when that would be, and also how it would be disclosed. Would it come together with a partner? Would it be something Nektar puts out? I’m just hoping to understand how the logistics would work. Thanks.
Howard W. Robin
executiveSure, I’ll take the second question first, and then I’ll turn it over to JZ. We do anticipate seeing data from the Medley bladder cancer trial during this year’s second half. We don’t yet have a specific date. And of course we’ll release it after the data has been cleaned, Merck KGaA has reviewed it, cleaned it, talked it over with us, and we’ve gone through the usual process. Still, my expectation is that all of that will take place within this year’s second half.
Jonathan Zalevsky
executiveGreat. Thanks, Howard.
Howard W. Robin
executiveAny comments?
Jonathan Zalevsky
executiveAbsolutely. Andy, I appreciate the question about human genetics—that's a really interesting one. So the validation for TNF-R2 comes from several distinct places. And before I get into the human side, let me mention some of the key preclinical results that have been generated. So TNF-R2 has been overexpressed, and it has also been knocked out. And you observe the corresponding phenotypes. When it's absent, animals struggle to keep TREG populations stable; they also struggle to produce any kind of surge of TREGs or TREG regulation in a model such as EAE, for instance. If you induce EAE in a TNF-R2 knockout, the disease becomes severely worsened, correct? And it's far, far more severe than otherwise; and whether you use MOG or PLP, you obtain comparable results. In the same way, when you boost its expression, you can lower the capacity to even provoke injury using different inflammatory agonists. Also, research that generated transmembrane TNF mice, some of the work Jonathan Sedgwick conducted in the early 2000s. Since that's the main ligand, you essentially get TNFR2 signaling as the main signal model. And once again, you saw quite similar effects where those animals were driving R2, and they stayed highly immunoregulatory. It was extremely difficult to establish an inflammatory model in that background. And then in people, we observe a sort of cluster of SNPs and other polymorphisms that appear together. So first, the most classic sort of TREG-like dysfunction is IPEX, right? And IPEX in humans occurs when you have a FOXP3 loss of function, very severe autoimmune, almost SCID type of disease. In fact, TNF-R2 SNPs and things that alter TNF-R2 expression or signaling can actually mimic IPEX, just not be as severe because clearly, knocking out Fox P3 is much more severe than losing TNF-R2. So I hope that answers your question. There are many, many streams of validation of TNF-R2. And probably, I suppose one more is actually just sort of coming from the field of using TNF inhibition, right? So we know that if you treat with a pan-TNF inhibitor like Humira or Remicade or Golimumab, pick your favorite one, right? They knock out transmembrane and soluble, and you see that that's contraindicated in a number of indications. And it's removal of that transmembrane that takes away the TNF-R2 signal that kind of short-circuits what you're trying to achieve therapeutically. So all of those roads kind of lead to Rome, and they've really led the field to come to understand that the two receptors, R2 and R1, they share very differentiating functions, and that R2 is like the natural antagonist to R1, and it seems to turn off that inflammatory pathway that TNF-R1 drives. It's highly tissue protective; so to create an agonist to capture that kind of biology could be really, really therapeutically ideal, and that's what we're trying to do. That's super helpful. Thank you.
Arthur He
analystGood afternoon, Howard and everyone. Arthur here, calling in from H.C. Wainwright. I appreciate you taking my question. To start, I'd like to direct something to Mary. Would your team be willing to look into studying REZPEG among patients who've had prior biologic exposure — whether as monotherapy or paired with a biologic, perhaps via a partnership or an IST?
Mary Tagliaferri
executiveHello, Arthur. That's a solid question, and it's one we discuss quite a bit among ourselves. As a general rule, the FDA mandates that you confirm biologically experienced patients undergo a washout spanning five and a half half-lives. That means anyone previously given a different biologic agent must remain off therapy for roughly 12 weeks. Certain clinical trials have allowed such patients to join, yet given how lengthy that washout on their earlier agent is, enrolling them proves rather challenging in practice, despite the fact that scores of patients have taken something like Dupixent. So for the phase 3 program, we're weighing how — or possibly whether — to bring those patients into our study. Beyond that, J.Z., Jennifer, and I have talked on many occasions about whether a combination trial might ever be pursued, for instance REZPEG alongside an IL-13 inhibitor. That topic has come up frequently in our internal discussions too, and it definitely sits on our list of trials to think about. That said, our main objective right now is superb execution of the phase 2b, reviewing the data, and, if results are positive, advancing swiftly into a program that gets REZPEG to patients as fast as we can.
Arthur He
analystThank you, Mary. Moving on to my next question, which concerns 165. I'm just wondering, at this point, which gating enabling studies exist for these programs as they head into the clinic next year?
Howard W. Robin
executiveJ.Z., would you like to address that?
Jonathan Zalevsky
executiveAbsolutely. Hi, Arthur. I appreciate you asking that. As I said before, we've moved the program forward to the point of finding candidates, and from there to describing them both in vitro and in vivo. In addition, we've conducted studies in large animals, such as a toxicology study that was non-GLP. We've also progressed into creating a manufacturing cell line, and we've started the early stages of manufacturing. So for our IND-enabling package — which is really the same as any other IND-enabling package — the big upcoming milestones are the GLP toxicology, and for us that will arrive at the close of the year. That's when it will begin. Beyond that, there's moving forward into GMP manufacture for the Phase 1 supply. But like I said, a great deal of work has already been completed, including much of the major work, for instance non-GLP toxicology studies in primates, and that gives us confidence to proceed through these IND-enabling studies. Awesome. Thanks, Jay-Z. I'll talk to you guys soon. Great. Thanks, Arthur.
Howard W. Robin
executiveAll right, and thanks to each of you for being here with us today. Our attention continues to be fixed on moving forward with REZPEG’s development and, naturally, additional immunology efforts such as NKTR-0165. I’d like to express gratitude to every one of our team members for their truly dedicated and strenuous efforts. The next 12 months ought to be a thrilling period, and we’re eager to bring you news about how we’re advancing. Thank you for being with us today. We appreciate it.
Operator
operatorThat wraps up the conference call for today. Thanks for joining in. You're free to disconnect at this point. Have a great day, everybody.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nektar Therapeutics transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Nektar Therapeutics earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nektar Therapeutics or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.